Onyx Biotec IPO Details
| IPO Issue Open Date: | 13 November 2024 |
| IPO Issue Close Date: | 18 November 2024 |
| IPO Issue Price Band: | ₹58 to ₹61 Per Share |
| Face Value: | ₹10 Per Equity Share |
| IPO Issue Size: | ₹29.34 Crores | 4,810,000 shares |
| Fresh Issue: | ₹29.34 Crores | 4,810,000 shares |
| Offer for Sale: | ₹[.] Crores |
| Issue Type: | Book Built Issue |
| IPO Listing At: | NSE SME |
| IPO Retail Quota: | Not more than 35% |
| QIB Quota: | Not more than 50% |
| NII Quota: | Not more than 15% |
| Employee Discount: | ₹[.] per share |
Onyx Biotec IPO Prospectus:
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
Onyx Biotec IPO Dates Timeline
| Issue Open Date: | 13 November 2024 |
| Issue Close Date: | 18 November 2024 |
| Basis of Allotment Date: | 19 November 2024 |
| Refunds Initiation: | 20 November 2024 |
| Shares Credit in Demat: | 20 November 2024 |
| IPO Listing Date Detail: | 21 November 2024 |
Onyx Biotec IPO Market Lot
| Application | Lot Size, Shares and Price Details |
| Retail (Min) | 1 lots and 2000 shares = ₹122,000 |
| Retail (Max) | 1 lots and 2000 shares = ₹122,000 |
| HNI (Min) | 2 lots and 4000 shares = ₹244,000 |
| B-HNI Minimum | – |
Onyx Biotec IPO GMP*
| GMP Date | GMP Today | Subject to Sauda | Kostak | Expected Gain |
| Today | ₹15 | ₹20,000 | ₹- | 25% |
| 13th Nov | ₹10 | ₹15,000 | ₹- | 16% |
| 11th Nov | ₹5 | ₹7,500 | ₹- | 8% |
| 10th Nov | ₹- | ₹- | ₹- | ₹- |
About Onyx Biotec
Onyx started its operation in the pharmaceutical industry with sterile water for injections in 2010. Since then, Onyx has been associated with the healthcare segment and has offered sterile pharmaceutical products. It has become a prominent supplier of sterile products to major corporations, including the top pharma companies at the pan-India level. Onyx is committed to providing high-quality products at affordable prices. Presently, their Company manufactures Sterile Water for Injections and acts as a pharmaceutical contract manufacturer offering a comprehensive range of Dry Powder Injections and Dry Syrup for India and overseas. Their products are being processed and manufactured in accordance with the best FDA practices available globally. Their system and product are tested constantly at each level to ensure international standards of quality in-house and FDA Certified Laboratories. Their core business is focused on providing end-to-end product development and manufacturing solutions to their clients. Their service also includes the preparation and filing of regulatory dossiers in the Indian and global markets.
Onyx Biotec IPO Strengths
To Be Updated Soon
Objects of the IPO Issue
- Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use;
- Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections;
- Prepayment or repayment of all or a portion of certain loans availed by the Company; and
- General Corporate Purposes.
Onyx Biotec Company Financial Report
The company reported revenue of ₹53.87 crores in 2024 against ₹39.62 crores in 2023. The company reported a profit of ₹3.03 crores in 2024 against a loss of ₹1.84 crores in 2023.
| Period Ended | Revenue | Expense | Profit After Tax | Assets |
| 2022 | ₹44.98 | ₹41.19 | ₹3.35 | ₹36.84 |
| 2023 | ₹39.62 | ₹37.07 | ₹1.84 | ₹58.72 |
| 2024 | ₹53.87 | ₹49.82 | ₹3.03 | ₹74.14 |
| May 2024 | ₹10.54 | ₹8.79 | ₹1.31 | ₹74.77 |
Onyx Biotec IPO Valuation – Key Performance Indicator
Check Onyx Biotec Services IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 10.58% |
| ROCE: | 12.19% |
| EBITDA Margin: | 15.41% |
| PAT Margin: | 5.64% |
| Debt to equity ratio: | 1.24 |
| Earning Per Share (EPS): | ₹2.54 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 12.19% |
| Net Asset Value (NAV): | ₹18.67 |
Peer Group Comparison
The below peer comparison table’s data are showing as per the DRHP and RHP.
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Suven Pharma | 11.80 | 83.92 | 14.64% | 80.56 | 1,051.35 Cr. |
| JB Chemicals | 35.66 | 53.63 | 18.90% | 188.37 | 3,484.18 Cr. |
Onyx Biotec IPO Registrar
Mas Services Limited
Phone: (011) 2610 4142
Email: ipo@masserv.com
Website: https://www.masserv.com/opt.asp
Onyx Biotec IPO Lead Manager
- Horizon Management Private Limited
Onyx Biotec IPO allotment status check on Mas Services website. Click on Mas Services Limited to get allotment status.
Promoters of Onyx Biotec
- Sanjay Jain
- Naresh Kumar
- Fateh Pal Singh.
Company Address
Onyx Biotec Limited
Bir Plassi Near Sainimajraropar,
Nalagarh Road
District Solan – 174101,
Phone: +91 172 265 6384
Email: generalinfo@onyxbiotec.com
Website: http://www.onyxbiotec.com/